Liu Y, Shan XQ, Li YJ, Gao WL, Zhao L. Role of human umbilical cord mesenchymal stem cells in diabetic kidney disease. World J Stem Cells 2025; 17(11): 113201 [DOI: 10.4252/wjsc.v17.i11.113201]
Corresponding Author of This Article
Lan Zhao, Academic Fellow, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Changling Road, Xiqing District, Tianjin 300381, China. lanzhao69@163.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 26, 2025 (publication date) through Nov 26, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Liu Y, Shan XQ, Li YJ, Gao WL, Zhao L. Role of human umbilical cord mesenchymal stem cells in diabetic kidney disease. World J Stem Cells 2025; 17(11): 113201 [DOI: 10.4252/wjsc.v17.i11.113201]
World J Stem Cells. Nov 26, 2025; 17(11): 113201 Published online Nov 26, 2025. doi: 10.4252/wjsc.v17.i11.113201
Role of human umbilical cord mesenchymal stem cells in diabetic kidney disease
Yan Liu, Xiao-Qian Shan, Yu-Jiao Li, Wei-Li Gao, Lan Zhao
Yan Liu, Xiao-Qian Shan, Yu-Jiao Li, Wei-Li Gao, Lan Zhao, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
Yan Liu, Xiao-Qian Shan, Yu-Jiao Li, Wei-Li Gao, Lan Zhao, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
Author contributions: Liu Y wrote the manuscript; Shan XQ, Li YJ, Gao WL, and Zhao L revised the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lan Zhao, Academic Fellow, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Changling Road, Xiqing District, Tianjin 300381, China. lanzhao69@163.com
Received: August 19, 2025 Revised: September 17, 2025 Accepted: October 31, 2025 Published online: November 26, 2025 Processing time: 99 Days and 15.2 Hours
Abstract
One of the most prevalent long-term effects of diabetes is diabetic kidney disease (DKD), which is linked to problems with the metabolism of amino acids, fats, and carbohydrates. The fundamental pathogenic mechanisms of DKD cannot be adequately treated by current clinical medicines; they can only slow the illness’s progression to end-stage renal disease. We will concentrate on integrating human umbilical cord mesenchymal stem cell (hUC-MSC)-related mechanisms and potential applications into the therapy of DKD, as this work shows that hUC-MSCs can be used to treat metabolic liver obesity associated with diabetes. Future studies on the connection between hUC-MSCs and related illnesses ought to be promoted.
Core Tip: This letter to the editor focuses on investigating how human umbilical cord mesenchymal stem cells (hUC-MSCs) contribute to diabetic kidney damage. At the same time, explore the similarities and differences of hUC-MSCs in treating metabolic dysfunction-associated steatotic liver disease and diabetic kidney disease. There are benefits of using hUC-MSCs to treat metabolic disorders. Future studies on the relationship between hUC-MSCs and the management of metabolic disorders ought to be promoted.
